Case report: molecular features and treatment options for small bowel adenocarcinoma
Author
dc.contributor.author
Córdova Delgado, Miguel Angel
Author
dc.contributor.author
Pizarro, Gonzalo
Author
dc.contributor.author
Pinto, Mauricio P.
Author
dc.contributor.author
Herrera, María Elisa
Author
dc.contributor.author
Garrido, Marcelo
Admission date
dc.date.accessioned
2021-11-10T19:46:57Z
Available date
dc.date.available
2021-11-10T19:46:57Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Frontiers in Oncology March 2021 Volume 11 Article 593561
es_ES
Identifier
dc.identifier.other
10.3389/fonc.2021.593561
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/182658
Abstract
dc.description.abstract
Small bowel adenocarcinoma (SBA) is a rare malignancy characterized by poor prognosis. Recent efforts have sought to elucidate the genetic landscape and the molecular drivers behind this disease. Herein, we report the main molecular alterations in two metastatic (stage IV) SBA patients. Interestingly, one of them had gene alterations that affected signaling pathways previously described for SBA. However, a second patient displayed previously unreported alterations in this particular tumor type. Based on these findings we discuss potential treatment options for patients affected by this rare, aggressive disease.
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
Frontiers Media
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States